Figure 2.

Forest plots to compare N1I3 and N3I1 regimens for key adverse event indicators. (a) Any adverse event, (b) grade 3 or higher adverse event, (c) serious adverse event, (d) adverse event leading to discontinuation, and (e) treatment-related death.

AE, adverse event; IV, generic inverse variance; N1I3 q3w x4, four doses of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks; N3I1 q3w x4, four doses of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks; 95% CI, 95% confidence interval.